NCT01029509View on ClinicalTrials.gov

Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Leukemia
Interventions
DRUG

OPB 31121

Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER